2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 000 | ||
| 100 | ||
| 1 000 | ||
| 1 173 | ||
| 827 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sitten · MuokattuAs I read it - and with a bit of quick mental math, they need about 6.50 kr. into the rights issue per existing share. Altså 21 kr + 6.50 kr = 27.50 kr. in total for 2 shares after the rights issue. And the underlying share therefore all else being equal should drop to 13.75 kr. But not today. The drop should only have come when the subscription right is detached - and the subscription right for the new share should thus cost 7.25 kr. But forget it. That never happens. The share price has already plummeted to a disastrous 8-9 kr. - and the above is already pure theory. That is always how it goes when biotech managements do not get wiser and do not learn how not to announce or execute a rights issue. Even Redeye is out today with criticism regarding management's ability to announce a rights issue without it going disastrously wrong.
·1 t sittenStill a bit crazy that we are dropping 60 % - the emission price hasn't been set yet, I suppose?Yes. Partly that. Partly that management and the so-called (expensively paid) advisors do not make an assessment of the extent to which existing shareholders will participate in a share issue, and instead start by offering the majority as a directed share issue with up to 15-20 % discount or more directly to those who are otherwise pulled in anyway as guarantors, and whom we today subsidize heavily anyway - but with the opposite, catastrophic result. If it should then turn out afterwards that we other small shareholders would have liked to have participated to a greater extent in a share issue, you can just (either immediately or after the expiry of a lock-up period) make a supplementary directed share issue towards the existing shareholders who want to contribute more money.
·1 t sitten · MuokattuSHOCK LOOK WHAT IS HAPPENING HERE LOOK NOW THE OLD FOOL OF A MARTIN HE HAS COST US SHAREHOLDERS A WHOLE LOT OF MONEY ON HIS ALL-NORDIC WAY OF RUNNING THE COMPANY KICK HIM THE HELL OUT OF HERE !!! MARTIN AND THE MANAGEMENT ARE HARDLY PARTICIPATING THEMSELVES IN THE RIGHTS ISSUE DISGUSTING
Sign up and ask questions here: https://events.inderes.com/bioinvent/q3-report-2026?utm_source=chatgpt.com- ·15 t sitten · MuokattuCrap and shit it is damn a crap case Old Martin must be thrown out the door he has done nothing good for the shareholders way too big costs too high pay for the board and management without getting anywhere the share price is almost at all time low just not good enough many times has Martin promised partner deal etc etc out with him and it can only go too slow unbelievable that quarter after quarter they can burn all those millions without getting further just below all criticism80% has already been subscribed so it won't be completely bad. No matter which biotech companies I read about on here you have a negative comment - shouldn't you put money into something safer?
·2 päivää sittenAs I see it, the result from their trial was not as good as the one Genmab came out with for the same treatment. Have I missed something?Will be exciting if we are going far down tomorrow even though over 80 % is already subscribed, but now we don't have to think about emission for the next year or so.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 277 314 | 2 277 314 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 277 314 | 2 277 314 | 0 | 0 |
2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten · MuokattuAs I read it - and with a bit of quick mental math, they need about 6.50 kr. into the rights issue per existing share. Altså 21 kr + 6.50 kr = 27.50 kr. in total for 2 shares after the rights issue. And the underlying share therefore all else being equal should drop to 13.75 kr. But not today. The drop should only have come when the subscription right is detached - and the subscription right for the new share should thus cost 7.25 kr. But forget it. That never happens. The share price has already plummeted to a disastrous 8-9 kr. - and the above is already pure theory. That is always how it goes when biotech managements do not get wiser and do not learn how not to announce or execute a rights issue. Even Redeye is out today with criticism regarding management's ability to announce a rights issue without it going disastrously wrong.
- ·1 t sittenStill a bit crazy that we are dropping 60 % - the emission price hasn't been set yet, I suppose?Yes. Partly that. Partly that management and the so-called (expensively paid) advisors do not make an assessment of the extent to which existing shareholders will participate in a share issue, and instead start by offering the majority as a directed share issue with up to 15-20 % discount or more directly to those who are otherwise pulled in anyway as guarantors, and whom we today subsidize heavily anyway - but with the opposite, catastrophic result. If it should then turn out afterwards that we other small shareholders would have liked to have participated to a greater extent in a share issue, you can just (either immediately or after the expiry of a lock-up period) make a supplementary directed share issue towards the existing shareholders who want to contribute more money.
- ·1 t sitten · MuokattuSHOCK LOOK WHAT IS HAPPENING HERE LOOK NOW THE OLD FOOL OF A MARTIN HE HAS COST US SHAREHOLDERS A WHOLE LOT OF MONEY ON HIS ALL-NORDIC WAY OF RUNNING THE COMPANY KICK HIM THE HELL OUT OF HERE !!! MARTIN AND THE MANAGEMENT ARE HARDLY PARTICIPATING THEMSELVES IN THE RIGHTS ISSUE DISGUSTINGSign up and ask questions here: https://events.inderes.com/bioinvent/q3-report-2026?utm_source=chatgpt.com
- ·15 t sitten · MuokattuCrap and shit it is damn a crap case Old Martin must be thrown out the door he has done nothing good for the shareholders way too big costs too high pay for the board and management without getting anywhere the share price is almost at all time low just not good enough many times has Martin promised partner deal etc etc out with him and it can only go too slow unbelievable that quarter after quarter they can burn all those millions without getting further just below all criticism80% has already been subscribed so it won't be completely bad. No matter which biotech companies I read about on here you have a negative comment - shouldn't you put money into something safer?
- ·2 päivää sittenAs I see it, the result from their trial was not as good as the one Genmab came out with for the same treatment. Have I missed something?Will be exciting if we are going far down tomorrow even though over 80 % is already subscribed, but now we don't have to think about emission for the next year or so.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 000 | ||
| 100 | ||
| 1 000 | ||
| 1 173 | ||
| 827 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 277 314 | 2 277 314 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 277 314 | 2 277 314 | 0 | 0 |
2026 Q3 - tulosraportti
Äänite tulossa
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten · MuokattuAs I read it - and with a bit of quick mental math, they need about 6.50 kr. into the rights issue per existing share. Altså 21 kr + 6.50 kr = 27.50 kr. in total for 2 shares after the rights issue. And the underlying share therefore all else being equal should drop to 13.75 kr. But not today. The drop should only have come when the subscription right is detached - and the subscription right for the new share should thus cost 7.25 kr. But forget it. That never happens. The share price has already plummeted to a disastrous 8-9 kr. - and the above is already pure theory. That is always how it goes when biotech managements do not get wiser and do not learn how not to announce or execute a rights issue. Even Redeye is out today with criticism regarding management's ability to announce a rights issue without it going disastrously wrong.
- ·1 t sittenStill a bit crazy that we are dropping 60 % - the emission price hasn't been set yet, I suppose?Yes. Partly that. Partly that management and the so-called (expensively paid) advisors do not make an assessment of the extent to which existing shareholders will participate in a share issue, and instead start by offering the majority as a directed share issue with up to 15-20 % discount or more directly to those who are otherwise pulled in anyway as guarantors, and whom we today subsidize heavily anyway - but with the opposite, catastrophic result. If it should then turn out afterwards that we other small shareholders would have liked to have participated to a greater extent in a share issue, you can just (either immediately or after the expiry of a lock-up period) make a supplementary directed share issue towards the existing shareholders who want to contribute more money.
- ·1 t sitten · MuokattuSHOCK LOOK WHAT IS HAPPENING HERE LOOK NOW THE OLD FOOL OF A MARTIN HE HAS COST US SHAREHOLDERS A WHOLE LOT OF MONEY ON HIS ALL-NORDIC WAY OF RUNNING THE COMPANY KICK HIM THE HELL OUT OF HERE !!! MARTIN AND THE MANAGEMENT ARE HARDLY PARTICIPATING THEMSELVES IN THE RIGHTS ISSUE DISGUSTINGSign up and ask questions here: https://events.inderes.com/bioinvent/q3-report-2026?utm_source=chatgpt.com
- ·15 t sitten · MuokattuCrap and shit it is damn a crap case Old Martin must be thrown out the door he has done nothing good for the shareholders way too big costs too high pay for the board and management without getting anywhere the share price is almost at all time low just not good enough many times has Martin promised partner deal etc etc out with him and it can only go too slow unbelievable that quarter after quarter they can burn all those millions without getting further just below all criticism80% has already been subscribed so it won't be completely bad. No matter which biotech companies I read about on here you have a negative comment - shouldn't you put money into something safer?
- ·2 päivää sittenAs I see it, the result from their trial was not as good as the one Genmab came out with for the same treatment. Have I missed something?Will be exciting if we are going far down tomorrow even though over 80 % is already subscribed, but now we don't have to think about emission for the next year or so.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 000 | ||
| 100 | ||
| 1 000 | ||
| 1 173 | ||
| 827 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 277 314 | 2 277 314 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 277 314 | 2 277 314 | 0 | 0 |